Your session is about to expire
← Back to Search
IMGN853 for Endometrial Cancer
Study Summary
This trial will test a new drug, IMGN853, on patients with a specific type of endometrial cancer. The goal is to see if the drug is active and safe.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My tumor is FRα-positive.I have an ongoing eye condition affecting my cornea.My initial surgery removed most or all of my tumor.I do not have any serious illnesses or active infections.I am 18 years old or older.I do not have serious heart or blood vessel problems.I have a history of neurological conditions.I have recovered from the side effects of my last chemotherapy.I am not pregnant or breastfeeding.I've had up to 3 treatments for my recurring cancer, not counting hormone therapy, and none targeted the folate receptor.You have had a severe allergic reaction to monoclonal antibodies in the past.I haven't had blood clotting or bleeding disorders in the last 6 months.My blood, liver, and kidney functions are all within normal ranges.I have another cancer that is getting worse or needed treatment in the last 3 years.My endometrial cancer has come back or didn't go away, confirmed by a scan.I am taking supplements that contain folate due to a deficiency.I have been diagnosed with non-infectious lung inflammation before.I do not have untreated brain-related cancer issues.My cancer is one of the specified types of uterine or endometrial cancer.It's been weeks since my last cancer treatment.I have a history of liver cirrhosis.I am fully active or restricted in physically strenuous activity but can do light work.I have not had a stroke in the past 6 months.
- Group 1: IMGN853
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this experiment exclude patients who are octogenarians?
"The patients that this study hope to include are between 18 and 100 years old."
How many people have signed up to participate in this clinical trial thus far?
"That is correct, the clinical trial detailed on clinicaltrials.gov is still ongoing and looking for patients to enroll. The 50 openings are at a single location. This information was most recently updated on 8/10/2022, with the original posting date being 7/15/2020."
Could I be a potential subject for this research?
"This study is recruiting 50 patients, between the ages of 18 and 100 who have endometrial neoplasms. It is required that participants also meet the following criteria: Patients must have one of the following pathologically documented, definitively diagnosed tumor types: Uterine serous carcinoma (Pure or Mixed), Grade 2 or Grade 3 endometrial adenocarcinoma, or Carcinosarcoma with high grade serous or Grade 2/3 endometrioid components, Have measurable disease, Have at least one "target lesion" to be used to assess response as defined by RECIST v1"
What is the federal government's official stance on IMGN853?
"IMGN853's safety is based on preliminary data and received a score of 2."
What other research has been conducted using IMGN853?
"At the moment, there are 9 different ongoing clinical trials for IMGN853. 2 of those studies have reached Phase 3 and are still recruiting patients. Although most of the research is based in Columbus, Ohio, 402 medical facilities across the United States are running these types of tests."
Are patients being actively signed up for this experiment?
"The clinical trial is currently underway and actively recruiting patients, as indicated by the listing on clinicaltrials.gov. This particular study was posted on 7/15/2020 and last updated on 8/10/2022."
Share this study with friends
Copy Link
Messenger